AJMC Contributor

Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

Building on clinical data, findings from patients receiving treatment with Bruton tyrosine kinase inhibitors (BTKis) in the real world are highlighting an improved heart-related safety profile associated with acalabrutinib (Calquence; AstraZeneca) compared with its earlier counterpart ibrutinib among patients with

Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study Read More »